vs
Side-by-side financial comparison of American Homes 4 Rent (AMH) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $455.0M, roughly 1.6× American Homes 4 Rent). American Homes 4 Rent runs the higher net margin — 31.7% vs 19.1%, a 12.6% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 4.2%). American Homes 4 Rent produced more free cash flow last quarter ($823.7M vs $188.1M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 3.6%).
American Homes 4 RentAMHEarnings & Financial Report
American Homes 4 Rent, doing business as AMH, is a real estate investment trust based in Las Vegas, Nevada, that invests in single-family rental homes. As of December 31, 2019, the company owned 52,552 homes in 22 states. Its largest concentrations are in Atlanta, Dallas-Fort Worth, and Charlotte, North Carolina.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
AMH vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $455.0M | $708.5M |
| Net Profit | $144.3M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | — | 21.6% |
| Net Margin | 31.7% | 19.1% |
| Revenue YoY | 4.2% | 32.0% |
| Net Profit YoY | 0.3% | 15.5% |
| EPS (diluted) | $0.33 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $455.0M | $708.5M | ||
| Q3 25 | $478.5M | $659.9M | ||
| Q2 25 | $457.5M | $603.3M | ||
| Q1 25 | $459.3M | $558.6M | ||
| Q4 24 | $436.6M | $536.6M | ||
| Q3 24 | $445.1M | $533.3M | ||
| Q2 24 | $423.5M | $528.1M | ||
| Q1 24 | $423.6M | $511.0M |
| Q4 25 | $144.3M | $135.1M | ||
| Q3 25 | $116.8M | $111.1M | ||
| Q2 25 | $123.6M | $90.3M | ||
| Q1 25 | $128.7M | $114.6M | ||
| Q4 24 | $143.9M | $117.0M | ||
| Q3 24 | $87.6M | $96.4M | ||
| Q2 24 | $108.5M | $88.4M | ||
| Q1 24 | $128.1M | $102.6M |
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 21.5% | ||
| Q2 25 | — | 20.9% | ||
| Q1 25 | — | 20.3% | ||
| Q4 24 | — | 23.4% | ||
| Q3 24 | — | 21.1% | ||
| Q2 24 | — | 19.9% | ||
| Q1 24 | — | 20.4% |
| Q4 25 | 31.7% | 19.1% | ||
| Q3 25 | 24.4% | 16.8% | ||
| Q2 25 | 27.0% | 15.0% | ||
| Q1 25 | 28.0% | 20.5% | ||
| Q4 24 | 33.0% | 21.8% | ||
| Q3 24 | 19.7% | 18.1% | ||
| Q2 24 | 25.6% | 16.7% | ||
| Q1 24 | 30.2% | 20.1% |
| Q4 25 | $0.33 | $4.65 | ||
| Q3 25 | $0.27 | $3.86 | ||
| Q2 25 | $0.28 | $3.10 | ||
| Q1 25 | $0.30 | $3.67 | ||
| Q4 24 | $0.33 | $3.67 | ||
| Q3 24 | $0.20 | $3.01 | ||
| Q2 24 | $0.25 | $2.75 | ||
| Q1 24 | $0.30 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $108.5M | $497.0M |
| Total DebtLower is stronger | $5.1B | — |
| Stockholders' EquityBook value | $7.0B | $459.1M |
| Total Assets | $13.2B | $2.0B |
| Debt / EquityLower = less leverage | 0.72× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.5M | $497.0M | ||
| Q3 25 | $45.6M | $285.4M | ||
| Q2 25 | $323.3M | $46.3M | ||
| Q1 25 | $69.7M | $441.4M | ||
| Q4 24 | $199.4M | $669.4M | ||
| Q3 24 | $162.5M | $656.9M | ||
| Q2 24 | $718.4M | $510.9M | ||
| Q1 24 | $124.8M | $407.0M |
| Q4 25 | $5.1B | — | ||
| Q3 25 | $4.8B | — | ||
| Q2 25 | $5.2B | — | ||
| Q1 25 | $4.9B | — | ||
| Q4 24 | $5.0B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $5.0B | — | ||
| Q1 24 | $4.5B | — |
| Q4 25 | $7.0B | $459.1M | ||
| Q3 25 | $7.2B | $293.6M | ||
| Q2 25 | $7.2B | $172.4M | ||
| Q1 25 | $7.2B | $593.6M | ||
| Q4 24 | $7.2B | $825.5M | ||
| Q3 24 | $7.0B | $881.4M | ||
| Q2 24 | $7.0B | $763.6M | ||
| Q1 24 | $7.0B | $671.5M |
| Q4 25 | $13.2B | $2.0B | ||
| Q3 25 | $13.3B | $1.8B | ||
| Q2 25 | $13.6B | $1.6B | ||
| Q1 25 | $13.3B | $1.9B | ||
| Q4 24 | $13.4B | $2.1B | ||
| Q3 24 | $12.8B | $2.1B | ||
| Q2 24 | $13.3B | $1.9B | ||
| Q1 24 | $12.8B | $1.8B |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.68× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 0.64× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $864.3M | $192.7M |
| Free Cash FlowOCF − Capex | $823.7M | $188.1M |
| FCF MarginFCF / Revenue | 181.0% | 26.6% |
| Capex IntensityCapex / Revenue | 8.9% | 0.6% |
| Cash ConversionOCF / Net Profit | 5.99× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $1.5B | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $864.3M | $192.7M | ||
| Q3 25 | $223.3M | $246.2M | ||
| Q2 25 | $271.9M | $148.5M | ||
| Q1 25 | $223.4M | $125.8M | ||
| Q4 24 | $811.5M | $190.7M | ||
| Q3 24 | $233.6M | $149.1M | ||
| Q2 24 | $274.0M | $116.4M | ||
| Q1 24 | $201.8M | $152.7M |
| Q4 25 | $823.7M | $188.1M | ||
| Q3 25 | $214.5M | $235.5M | ||
| Q2 25 | $257.7M | $142.4M | ||
| Q1 25 | $215.9M | $115.8M | ||
| Q4 24 | $777.5M | $183.0M | ||
| Q3 24 | $225.3M | $138.5M | ||
| Q2 24 | $263.3M | $103.5M | ||
| Q1 24 | $191.0M | $147.2M |
| Q4 25 | 181.0% | 26.6% | ||
| Q3 25 | 44.8% | 35.7% | ||
| Q2 25 | 56.3% | 23.6% | ||
| Q1 25 | 47.0% | 20.7% | ||
| Q4 24 | 178.1% | 34.1% | ||
| Q3 24 | 50.6% | 26.0% | ||
| Q2 24 | 62.2% | 19.6% | ||
| Q1 24 | 45.1% | 28.8% |
| Q4 25 | 8.9% | 0.6% | ||
| Q3 25 | 1.8% | 1.6% | ||
| Q2 25 | 3.1% | 1.0% | ||
| Q1 25 | 1.6% | 1.8% | ||
| Q4 24 | 7.8% | 1.4% | ||
| Q3 24 | 1.9% | 2.0% | ||
| Q2 24 | 2.5% | 2.4% | ||
| Q1 24 | 2.6% | 1.1% |
| Q4 25 | 5.99× | 1.43× | ||
| Q3 25 | 1.91× | 2.22× | ||
| Q2 25 | 2.20× | 1.65× | ||
| Q1 25 | 1.74× | 1.10× | ||
| Q4 24 | 5.64× | 1.63× | ||
| Q3 24 | 2.67× | 1.55× | ||
| Q2 24 | 2.52× | 1.32× | ||
| Q1 24 | 1.58× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMH
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
